MARATTO

article · Green Processing and Synthesis

Influential eradication of resistant <i>Salmonella Typhimurium</i> using bioactive nanocomposites from chitosan and radish seed-synthesized nanoselenium

Abstract

Abstract Biosynthesized nanomaterials and nanocomposites (NCs) could have promising potentialities to overcome the multi-drug-resistant (MDR) pathogenic bacteria, particularly Salmonella Typhimurium . Radish seed ( Raphanus sativus ) mucilage (RSM) was employed for synthesizing/capping selenium nanoparticles (SeNPs) and their nanoconjugates with chitosan (Ct) were assessed for inhibiting MDR S. typhimurium . The SeNPs were effectually biosynthesized using RSM and have 4.21 nm mean size and −25.6 mV surface charge. Different NC formulations of Ct/RSM/SeNPs were generated and validated using infrared spectroscopy and electron microscopy. The entire formulations could suppress S. Typhimurium growth, including MDR strains. F3 NCs (with 53.64 nm diameter and +21.1 mV surface charge) had the strongest anti- S. Typhimurium activity that exceeded the action of cephalosporin, and the subsequent antibacterial formulation was F2 (with 41.77 nm diameter and −17.3 mV charge). The NCs of Ct/RSM/SeNPs could severely destruct, deform, and lyse S. Typhimurium cells’ structures throughout 10 h of exposure. The innovative fabricated NCs of Ct/RSM/SeNPs are auspiciously suggested as effectual biocides to eradicate MDR S. Typhimurium in various food-processing facilities.

Research topics

  • Nanoparticles: synthesis and applications
  • Advanced biosensing and bioanalysis techniques
  • Advanced Nanomaterials in Catalysis

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1515/gps-2024-0090

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.